To date, breast cancer (BC) research is mainly studied with cell lines. These cells were passaged multiple times, acquiring phenotypes, additional mutations and epigenetic changes. These changes make the passaged cell lines different from the original malignancy. Thus cell lines, although useful as models could be improved with additional studies with primary BC. It is difficult to obtain malignant cells from breast tissues without contamination from surrounding healthy cells. Selection and expansion of malignant cells from surgical tissues have proved to be daunting tasks. This study describes a reliable and reproducible method for isolating and expanding malignant cells from surgical breast tissues. The method uses co-cultures with BM stroma to select for the cancer cells while the healthy cells undergo rapid cell death. Studies are described to show the cloning efficiencies and sensitivity of the method using surgical samples of varying sizes, different stages of BC, and samples from needle biopsies.
INTRODUCTION
Breast cancer (BC) metastasis to the bone marrow (BM) correlates with poor prognosis (1) . Seemingly curative therapies in patients with both metastatic and nonmetastatic BC have recurrence of BC cells from the BM (1) . Such resurgence could occur even twenty years after remission (1, 2) . Based on these reports, it is hypothesized that BC cells (BCCs) entering and surviving in BM are either subsets of BCCs with unique properties, or they are located in an area to protect them from current treatment modalities. The ability of BCCs resurging from the BM is consistent with preference for this organ (2) . Since similar resurgence occurred even in cases with early stages of BC it appears BCCs might have entered BM long before the tumor could be detected by current clinical methods.
BM toxicity limits the dose of current cancer therapies (3) . Thus, if a special type of BCC is within specialized region of the BM, then targeting BCCs in BM would be a clinical challenge. To mimic in vivo behavior of BCCs, it is essential to use primary BCCs in experiments since these cells would have limited divergence as might occur with cell lines.
Studies using BC cell lines with varying degrees of metastatic potentials are models in the majority of laboratories. Use of cell lines is convenient due to their availability through tissue depository banks, and 9 simplicity with regards to culture maintenance. Some cell lines have been distributed within laboratories so that relevant information regarding their source and number of passages are lost. This could lead to heterogeneity within a particular line and lead to seemingly irreproducible data among laboratories. In summary, BC cell lines might not show consistent results, and might not accurately represent the behavior of cancer cells in vivo.
Another disadvantage for BCCs subjected to multiple passages relates to their genomic instability resulting in a population of cells with varying degrees of tumorigenic potential. It is advisable to verify studies from cell lines with primary BCCs. Another limitation when primary BCC are used pertains to the size of surgical tissues. For small samples, clinical analyses have first preference leaving no sample for experimental analyses. These limits are evident when samples are obtained by noninvasive methods such as needle biopsies. Another major disadvantage is difficulty in separating malignant and normal cells in surgical tissues.
Studies from our laboratory reported a novel method to isolate primary BCCs in co-cultures with BM stroma. The method has been proven effective and sensitive even for needle biopsies. The co-culture method is also applied in studies to understand the behavior of BCCs within BM. Methods to use primary BCCs is underscored by recent findings on SDF-α-CXCR4 interactions in BC metastasis (4) . Malignant breast tissue, unlike healthy tissue show high expression of CXCR-4. Since stromal cells produce SDF-1α (8), BCCs expressing CXCR4 could be attracted and retained to organs that express SDF-1, such as BM, lung, and liver (4) . The density of CXCR-4 on BCC is proportional to the invasiveness of the cancer (5) . Recent studies with mice show that there might be two subtypes of BCC that enter the BM (6) . The aforementioned examples on SDF-1-CXCR4 argue for studies with primary BCCs to understand the fine-tuned mechanisms facilitating BC metastasis to the BM, and late stage resurgence in BM.
Previous studies show BCCs with high proliferative potential is found within the central/cellular areas of the BM cavity (6) . Another BC subset with long doubling times is located close to the endosteum (6) . Defining the properties of BCC subtypes in the BM and understanding the mechanisms involved in BCC entry in the BM are keys to improve cancer treatment and eradication. The method to isolate malignant cells will provide the opportunity to compare BCCs at different stages of the cancer, and also those that enter the BM at different periods during the course of the disease. To identify the cells entering early in different organ could lead to understandings on the mechanisms of entry and the signature of these cells, leading to cancer prevention, partly by early detection.
MATERIALS AND METHODS

Reagents and antibodies
α-Minimum Essential Medium (α-MEM), glutamine and hydrocortisone were purchased from Sigma (St. Louis, MO). Fetal Calf sera (FCS) and Horse Sera (HS) were purchased from Hyclone Laboratories (Logan, UT). PEcytokeratin mAb, PE-rat anti mouse kappa and PE-CD14 mAb were purchased from BD Bioscience (San Jose, CA). Prolyl-4-hydroxylase mAb was purchased from Dako (Glostrup, Denmark). Anti-Epithelial and anti-fibroblast were purchased from Miltenyi Biotec, Auburn, CA) respectively.
Cell lines
The following cell lines were purchased from American Type Culture Collection (Manassas, VA): Tumorigenic cell lines, T47D and MDA-MB-330 and non-tumorigenic cell lines, MCF12A and MCF 10A.
Primary breast tissue
Excess tissues were taken from samples of surgical procedures. The surgical interventions were done in patients diagnosed with different stages of BC. At the time of surgery patients were not on any medication. Samples were provided from two sources. The major source of breast tissue was from Brookdale Hospital (Brooklyn, NY). Use of breast tissues followed a protocol approved by the institutional review board of University of Medicine and Dentistry of New Jersey (Newark, NJ) and Brookdale Hospital (Brooklyn, NY). Patient samples were also provided by the Cooperative Human Tissue Network. Table 1 shows representative subsets of patients' profile of tissues. Excess samples from needle biopsies were also obtained from Brookdale Hospital. Cloning efficiencies 82% 74% 87%
Fibroblasts were depleted from surgical breast tissues. Cells retrieved (starting population) were placed in co-cultures with BM stroma. At confluence, cytokeratin positive cells were selected and then placed in multiple passages of co-cultures with fresh BM stroma. The mean ± SD of total cytokeratin positive cells are shown for passage 4 (P4). At P4 cells were studied in clonogenic assays.
Cell suspension from surgical breast tissues
Cells (normal and malignant) were retrieved from the breast tissues using the following two methods: a) flushing with a 1-cc syringe containing any type of cell culture media; and b) dislodging cells with serrated-end forceps. Fibroblasts were removed using double positive selection with anti-fibroblast microbeads. Depletion of fibroblasts was verified by flow cytometry with FITCanti-fibroblasts and PE-anti-cytokeratin. Viability of selected cells was >95%, by trypan blue exclusion. Biopsies from three different patients with stage 0 BC (Table 1) were obtained and also cleared of fibroblasts (as above). Fibroblast-depleted cells from patients with BC are hereafter referred as breast cells because the cells might contain both malignant and normal cells. After coculture and selection of anchorage independent growth, the cells were referred as primary BCCs (6) . The cells were passaged at least four times before use in assays. Cryopreservation up to two years did not alter their anchorage-independent properties, nor their ability to form co-cultures.
Preparation of BM stroma
BM aspirate, 10 7 nucleated cells from healthy donors between ages 18-25 years were added to 25 cm 2 tissue culture flasks (Falcon 3109). After selection, stromal cells were resuspended in stromal culture medium II, consisting α-MEM with 20% FCS. Plates were incubated 3 days at 37°C; mononuclear cells were separated by Ficoll-Hypaque density gradient and then replated in fresh medium. Cells were incubated until confluency, approximately 3 weeks. During this time, cultures were fed weekly by replacing fifty percent of the culture medium with fresh medium. At confluence trypsinsensitive, adherent cells were passed at least five times. Flow cytometry studies indicate stromal cells were CD14 (-) and prolyl 4-hydroxylase (+).
Co-cultures with established cell lines
BCCs refer to both cell lines and primary cells. Equivalent numbers of BCCs and BM stromal were cocultured in stromal growth media with weekly replacement of 50% of the culture media. For cultures in 25 cm 2 tissue culture flasks, cultures were initiated with 10 2 cells of each cell subset. To perform timeline studies, at different times, cells are trypsinized and the BCCs are positively selected by subjecting the cells twice to positive selection with Dynabead conjugated anticytokeratin, as described (7) . Both stromal and BCC cell populations are counted and the purity of each were verified by flow cytometry for epithelial and fibroblasts antibodies. For epithelial, cells were labeled with PEcytokeratin mAb. Indirect labeling was done for stroma, first with prolyl 4-hydroxylase mAb followed with PErat anti-mouse IgG. Cells separated by this isolation procedure show purity of more than ninety nine percent.
Selecting BCCs from primary cultures
Epithelial cells retrieved from surgical breast tissues, 10 3 -10 6 , were added to 25 cm 2 tissue culture flasks with 7 ml of stromal media and stromal cells at 20-40% confluence. At confluence, the breast cells are isolated as described for co-cultures with cell lines. Cells retrieved are counted and the process repeated three times. Cells are then studied for cloning efficiency in methylcellulose matrix (see below). If the efficiency is <90%, the selection process was repeated until cloning efficiencies were >90%.
Clonogenic assays
Clonogenic assays were performed as described (6) . Briefly, 10 3 cells/ml were resuspended in 1.2% methylcellulose containing media taken from the cocultures. One ml of cell suspension was added to 35 mm suspension dishes (Nunc, Cat#171099) and the cultures were incubated for 1 wk at 37°C. Colonies with >15 cells were counted and the cloning efficiency presented as percent of total cells placed in culture.
RESULTS AND DISCUSSION
This study depleted cells from breast biopsies of fibroblasts rather than subjecting the cells positively with anti-epithelial cells. Although this appears to place the breast cells under unnecessary stress we have found loss of malignant cells when epithelial cells are selected. Thus, if large breast tissues are obtained from the surgeon, positive selection could be performed. However, if there are variation in surface epithelial, crucial subsets might be missed in positive selection.
Cells from breast tissues were placed in suspension and then depleted of fibroblasts. The breast cells were either cultured alone in stromal media or added to stromal cultures. Cultures in stromal media alone did not survive. However, those cultured in the presence of BM stroma continued to survive until confluent. Initial plating of co-cultures comprised BM stroma and BCCs (T47D and MDA-MB-330) or non-tumorigenic cells (MCF 10A or MCF 12A). Figure 1A shows T47D as representative of co-cultures with BCCs. Since nontumorigenic cells did not survive in co-cultures, these experiments are not shown. Controls cultures Subsequent passage is represented in Figure 1B . By the fourth passage, the cells are able to be cultured in the absence of BM stroma (Fig. 1C ). Parallel cultures with a cell line, T47D are represented in Figure 1D -1F. Cells in both 1C and 1F were similar by morphology and by phenotype, positive for cytokeratin (not shown). Fig. 1 : BC cells from patients were plated on BM stroma in co-culture. Cells were passaged together four times. At passage 5, BCC were isolated and characterized. Parallel studies were performed using established BC lines for comparison. A) Initial co-culture of patient BCC and BM stroma. B) Patient BCC and BM stroma at P4. C) Primary BCC isolated from stroma after co-culture. D) Initial co-culture of T47D and BM stroma. E) T47D and BM stroma at P4. F) T47D isolated from stroma after co-culture. Primary cells represent studies from seven patients. Cell line studies represent studies with two different cells, each performed seven times.
The results shown in Figure 1 do not prove that the cells could be cultured in an anchorage-independent manner. To this end, cells represented in Figure 1C were assayed in methylcellulose matrix for clonogenic potential. To prove that anchorage-independent clones can be derived from different stages of BC, the assays were performed with cells selected from early to late stages of BC. Table 1 describes the steps beginning from the number of cells selected from Stages M0, I and III BC patients. The results showed a cloning efficiency of 82% for the malignant cells from the Stage M0 patients, 74% stage MI, and 87% Stage MIII. This indicates that anchorage independent clones can be selected and expanded from various stages of BC.
The co-culture method presented in this report was originally designed to select malignant cells from surgical breast tissues. The method has been expanded to select and expand malignant cells from breast biopsies. The method has been shown to be sensitive to select malignant cells from small tissue samples, including patients with Stage M0 BC. The method is also sensitive to select malignant cells from needle biopsies.
In summary, co-culture of cells from breast tissues with the stroma still resulted in the selection of the anchorage independent malignant cells when the tissues are derived from different stages of BC (Table 1) . Co-cultures from tissues taken from Stage M0 BC patients exhibited significantly slower growth rate compared to co-cultures with cells from Stage III BC. Figure 2 shows the growth of BCCs populations for BCCs taken from patients with Stages M0 and III. 12 This is probably due to two reasons: 1. The co-cultures are initiated with significantly lower number of malignant cells, 2. The early stage of BC might have slower growing malignant cells. The co-culture described in this report will begin to characterize BCCs from different stages of BC. Another application for the coculture with BM stromal cells is an excellent tool for selecting malignant cells and expanding them in culture from small samples for clinical and/or research analyses. An important aspect of our model of selecting BCCs in stromal co-culture is whether the method is selecting specific malignant cells with preference for BM. The information is important in light of recent studies shown organ-specific potential of distinct BCCs (9). The method described in this report could be valuable for future research to study differences in BCCs in various sites of metastasis. Of note is that passage of the cells in the method is meant to eliminate non-tumorigenic cells since passage 1 cells are anchorage-dependent.
